Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Study Shows Topical Analgesic as Effective as Electrical Stimulation (TENS) at Reducing Low Back Pain
  • USA - English


News provided by

Sport and Spine Rehab

Aug 15, 2013, 16:20 ET

Share this article

Share toX

Share this article

Share toX

Performance Health Biofreeze
Performance Health Biofreeze

Akron, Ohio (PRWEB) August 15, 2013 -- Clinical researchers at Sport and Spine Rehab Clinical Research Foundation in Rockville, MD, recently compared Biofreeze topical analgesic and transcutaneous neuromuscular electrical stimulation (TENS) treatments in patients with low back pain.

Understanding how we can effectively integrate Biofreeze into our patients' treatment plans to maximize their response to care and reduce their out of pocket cost is good for every patient and good for the healthcare system at large.

Post this

The study showed that Biofreeze Pain Reliever was as effective as TENS treatment in reducing pain. However, the researchers, noting the potential differences in treatment cost (the average retail cost of Biofreeze is significantly lower than that of the TENS unit), suggested it would be a prudent choice to incorporate Biofreeze Pain Reliever as a replacement for TENS.1.

The researchers presented their findings at the 2013 ACC-RAC conference in Washington DC and their abstract was published in the Journal of Chiropractic Education.

“Back pain is a constant threat to an individual’s confidence and desire to continue with a training or rehab program, so the first step in any rehab program is to manage and control that pain,” stated Dr. Barton N. Bishop, Chief Clinical Officer of Sport and Spine Rehab. “Our intent with this study was to evaluate the effectiveness of Biofreeze Pain Reliever, a low cost topical analgesic as compared to TENS, to determine how we could get the best outcomes at the lowest cost for the patient. Based on our past Biofreeze effectiveness studies, we were not surprised to see that Biofreeze and TENS had statistically similar outcomes for pain, disability and fear avoidance. As we state in the study’s conclusion, we believe Biofreeze is a cost effective prudent replacement for TENS treatment.”

Twenty-two patients suffering with low back pain were randomly assigned to either Biofreeze treatments or TENS treatments in addition to a standardized rehabilitation program including exercise and manual therapy. The researchers found that both treatment groups significantly reduced their pain, disability, and fear avoidance behavior at similar levels. “In this day and age of evidence-based, cost-conscious care, it is critical to perform clinical research to help create best practices and best outcomes,” added Dr. Jay Greenstein, CEO of Sport and Spine Rehab. “Understanding how we can effectively integrate Biofreeze into our patients’ treatment plans to maximize their response to care and reduce their out of pocket costs is good for every patient and good for the healthcare system at large.”

Background: TENS or transcutaneous neuromuscular electrical stimulation is a common method of pain reduction used by rehabilitation professionals. Clinically used and recommended Biofreeze Pain Reliever uses USP-grade menthol as its active ingredient to provide reliable short-term pain relief. One theory to explain how TENS and Biofreeze topical analgesic decrease pain is the gate control theory. The gate control theory suggests that specific nerve stimulation over-rides painful nerve signals to the brain, thus reducing the perception of pain.

About the Academy
The Thera-Band® Academy was formed to scientifically document the benefits of resistance exercise and pain relief, guide the company in its development of new products and exercise programs, and to promote therapeutic exercise and pain management through professional and consumer education. The Academy web site is a unique resource that connects healthcare professionals and consumers to the ever growing body of knowledge on exercise. Registration is free and provides access to the largest database of rehab exercises, protocols, research and education in the world.

About Performance Health
Featuring leading brands like Thera-Band®, Biofreeze® and Pedigenix®, Performance Health offers a broad portfolio of products for the therapy, rehabilitation, wellness, massage, podiatric and performance markets. In addition to market-leading products, Performance Health provides practice building support, evidence-based protocols, clinical and product education, turn-key dispensing and pain management solutions.

Reference: Greenstein et al. Evaluation of transcutaneous electrical nerve stimulation vs. Biofreeze in the treatment of back pain. (Abstract). 2013. J Chiropr Ed. 27(1):90-91.

Disclosure: Performance Health provided product for this study.

Curt Christiansen, Sport and Spine Rehab, http://www.ssrehab.com, 240-447-5193, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.